ORIC Pharmaceuticals, Inc. (ORIC) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-23

How it makes money

It currently generates no commercial revenue, as it is a clinical-stage entity that has not yet brought a therapeutic product to market.

As a clinical-stage biopharmaceutical company, it focuses on research and development to address therapeutic resistance in cancer. Its economic model is based on developing drug candidates that it hopes to commercialize after successful clinical trials and regulatory approval.

It currently depends on capital infusions to fund operations rather than product sales, as it has not yet achieved market-ready status for its pipeline candidates.

What protects it: the moat

Management claims its competitive advantage relies on its specialized expertise and a proprietary pipeline of candidates licensed from third parties.

It relies on intellectual property and development rights obtained through agreements, such as its licenses with Mirati Therapeutics and Voronoi. It asserts that its team’s deep understanding of cancer resistance mechanisms provides a strategic edge, though it acknowledges the significant competition inherent in the pharmaceutical sector.

What growth costs

It must heavily reinvest in clinical trials, regulatory filings, and R&D to advance its drug candidates toward potential future commercialization.

Its primary costs involve funding high-risk clinical trials and maintaining an expert research team. These activities require substantial and ongoing capital investment to navigate the multi-year process of moving from phase 1b studies to registrational phase 3 trials and eventually through FDA approval pathways.

The company does not specify fixed maintenance costs versus growth costs, as its entire operational structure is currently dedicated to the development of its clinical-stage pipeline.

What could damage it

Failure to demonstrate safety or efficacy in clinical trials would permanently impair its ability to monetize its pipeline candidates.

Since its value is tied entirely to the success of its experimental therapies, any clinical outcome that fails to meet regulatory standards or safety benchmarks effectively invalidates the research investment, rendering the specific program commercially non-viable.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Other companies in Biotechnology